Key facts
- Abiochem Biotechnology Co.’s last known valuation is $706.9M (Dec 2022).
- It has raised $215.9M; the latest was Later Stage VC ($62.8M) in Jul 2025.
- Notable investors include Addor Capital, Temasek Holdings, CMB International Capital, Highlight Capital, Zizhu Xiaomiao PE — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Abiochem Biotechnology Co.
- ·The full record, as it builds
Funding rounds
No funding rounds for Abiochem Biotechnology Co. are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Abiochem Biotechnology Co.
Operator of a bio-intelligent manufacturing company focused on manufacturing chemical and biological products. The company studies and develops new biocatalysis and synthetic biology processes, providing clients with one-stop customized genetic and enzyme engineering services in pharmaceuticals, agriculture, and food fields.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2015
- Employees
- 346
- Website
- abiochem.cn/
- Ownership
- Privately Held (backing)
Abiochem Biotechnology Co. doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Abiochem Biotechnology Co. shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Abiochem Biotechnology Co. in its N-PORT filings yet. We sweep new filings monthly.